328 related articles for article (PubMed ID: 35845354)
1. Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age <65 with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction: A Cost-Benefit Analysis.
Glover S; Borrego ME; Ray GM; Roberts MH
Clinicoecon Outcomes Res; 2022; 14():465-477. PubMed ID: 35845354
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
3. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
Nassif ME; Kosiborod M
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():19-23. PubMed ID: 31081589
[TBL] [Abstract][Full Text] [Related]
4. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials.
Lu Y; Li F; Fan Y; Yang Y; Chen M; Xi J
Eur J Intern Med; 2021 May; 87():20-28. PubMed ID: 33824055
[TBL] [Abstract][Full Text] [Related]
5. Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure.
Vaduganathan M; Greene SJ; Zhang S; Solomon N; Chiswell K; Devore AD; Butler J; Heidenreich PA; Huang JC; Kittleson MM; Joynt Maddox KE; Mcdermott JJ; Owens AT; Peterson PN; Solomon SD; Vardeny O; Yancy CW; Fonarow GC
J Card Fail; 2022 Apr; 28(4):554-563. PubMed ID: 34785402
[TBL] [Abstract][Full Text] [Related]
6. SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?
Al Rifai M; Newby LK; Nair AP; Misra A; Rogers JG; Fedson S; Virani SS
Curr Atheroscler Rep; 2022 Aug; 24(8):627-634. PubMed ID: 35653033
[TBL] [Abstract][Full Text] [Related]
7. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials.
Zheng C; Lin M; Chen Y; Xu H; Yan L; Dai H
Cardiovasc Diabetol; 2021 Apr; 20(1):83. PubMed ID: 33888126
[TBL] [Abstract][Full Text] [Related]
8. Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.
Komuro I; Kadowaki T; Bodegård J; Thuresson M; Okami S; Yajima T
Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():19-27. PubMed ID: 33835641
[TBL] [Abstract][Full Text] [Related]
9. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
Butler J; Handelsman Y; Bakris G; Verma S
Eur J Heart Fail; 2020 Apr; 22(4):604-617. PubMed ID: 31926059
[TBL] [Abstract][Full Text] [Related]
10. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN-HF study.
Correale M; Antohi EL; Inciardi RM; Mazzeo P; Coiro S; Ishihara S; Petroni R; Monitillo F; Leone M; Triggiani M; Sarwar CMS; Dungen HD; Talha KM; Brunetti ND; Butler J; Nodari S;
ESC Heart Fail; 2023 Jun; 10(3):2066-2073. PubMed ID: 36924023
[TBL] [Abstract][Full Text] [Related]
12. SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL.
Cavender MA; Norhammar A; Birkeland KI; Jørgensen ME; Wilding JP; Khunti K; Fu AZ; Bodegård J; Blak BT; Wittbrodt E; Thuresson M; Fenici P; Hammar N; Kosiborod M;
J Am Coll Cardiol; 2018 Jun; 71(22):2497-2506. PubMed ID: 29852973
[TBL] [Abstract][Full Text] [Related]
13. Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion.
Hernandez M; Sullivan RD; McCune ME; Reed GL; Gladysheva IP
Diagnostics (Basel); 2022 Apr; 12(4):. PubMed ID: 35454037
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Kosiborod M; Lam CSP; Kohsaka S; Kim DJ; Karasik A; Shaw J; Tangri N; Goh SY; Thuresson M; Chen H; Surmont F; Hammar N; Fenici P;
J Am Coll Cardiol; 2018 Jun; 71(23):2628-2639. PubMed ID: 29540325
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus.
Lee SE; Nam H; Choi HS; Kim H; Kyoung DS; Kim KA
Diabetes Metab J; 2022 Jul; 46(4):567-577. PubMed ID: 35130688
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Singh AK; Singh R
Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
[TBL] [Abstract][Full Text] [Related]
17. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
Woo V; Connelly K; Lin P; McFarlane P
Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
[No Abstract] [Full Text] [Related]
18. Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study.
Nair R; Mody R; Yu M; Cowburn S; Konig M; Prewitt T
Diabetes Ther; 2022 Dec; 13(11-12):1921-1932. PubMed ID: 36131064
[TBL] [Abstract][Full Text] [Related]
19. Adverse effects of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: a systematic review and meta-analysis.
Pozzi A; Cirelli C; Merlo A; Rea F; Scangiuzzi C; Tavano E; Iorio A; Kristensen SL; Wong C; Iacovoni A; Corrado G
Heart Fail Rev; 2024 Jan; 29(1):207-217. PubMed ID: 37917192
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review.
Panico C; Bonora B; Camera A; Chilelli NC; Prato GD; Favacchio G; Grancini V; Resi V; Rondinelli M; Zarra E; Pintaudi B
Cardiovasc Diabetol; 2023 Jun; 22(1):164. PubMed ID: 37391739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]